From this research we know that

• 2.7  

  COVID-19 worsens Hypokalemia

  updated by Generic SubmitterPRO 8 months ago Cohort (2020) Cohort (2020)

   (BioMindmap Proof Quality is Acceptable.)
• 2020
  Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China
• RESULTS: One hundred seventy-five patients (87 female patients [50%]; mean [SD] age, 45 [14] years) were classified as having severe hypokalemia (31 patients [18%]), hypokalemia (64 patients [37%]), and normokalemia (80 patients [46%]). Patients with severe hypokalemia had statistically significantly higher body temperature (mean [SD], 37.6 °C [0.9 °C]) than the patients with hypokalemia (mean [SD], 37.2 °C [0.7 °C]; difference, 0.4 °C; 95% CI, 0.2-0.6 °C; P = .02) and the patients with normokalemia (mean [SD], 37.1 °C [0.8 °C]; difference, 0.5 °C; 95% CI, 0.3-0.7 °C; P = .005). Patients with higher levels of hypokalemia also had higher creatine kinase levels (severe hypokalemia, mean [SD], 200 [257] U/L [median, 113 U/L; interquartile range {IQR}, 61-242 U/L]; hypokalemia, mean [SD], 97 [85] U/L; and normokalemia, mean [SD], 82 [57] U/L), higher creatine kinase–MB fraction (severe hypokalemia, mean [SD], 32 [39] U/L [median, 14 U/L; IQR, 11-36 U/L]; hypokalemia, mean [SD], 18 [15] U/L; and normokalemia, mean [SD], 15 [8] U/L), higher lactate dehydrogenase levels (mean [SD], severe hypokalemia, 256 [88] U/L; hypokalemia, 212 [59] U/L; and normokalemia, 199 [61] U/L), and higher C-reactive protein levels (severe hypokalemia, mean [SD], 29 [23] mg/L; hypokalemia, mean [SD], 18 [20] mg/L [median, 12, mg/L; IQR, 4-25 mg/L]; and normokalemia, mean [SD], 15 [18] mg/L [median, 6 U/L; IQR, 3-17 U/L]). Of 40 severely and critically ill patients, 34 (85%) had hypokalemia. Patients with severe hypokalemia were given potassium at a dose of 40 mEq per day, for a total mean (SD) of 453 (53) mEq potassium chloride, during the hospital stay. The patients responded well to potassium supplements as they recovered.
  CONCLUSIONS: The present study has identified the prevalence of hypokalemia in patients with COVID-19. The correction of hypokalemia is challenging because of continuous renal loss of K⁺ resulting from the degradation of ACE2 by the binding of SAR-CoV-2. The end of the loss of K⁺ may be a reliable, timely, and sensitive biomarker that reflects the end of disruption on the RAS system by SAR-CoV-2. Because of the possible effects on cardiovascular functions, neurohormonal activation, and other vital organs by hypokalemia, clinicians should pay attention to hypokalemia and the patients’ response to K⁺ supplements.
  
  FINDINGS: In this cohort study, hypokalemia was prevalent among patients with coronavirus disease 2019 and was associated with disease severity. It was challenging to correct hypokalemia because of the continuous renal potassium loss.

• ---

  ncbi.nlm.nih.gov/pmc/articles/PMC7290402

  10.1001/jamanetworkopen.2020.11122
URL is considered a Good Source.
Add Biolinks Add Biolink
Mindmap of the URL
Read on Sci-Hub

Hint — Biolinks Buttons

×

Did you notice how many controls you have over each Biolink?

• — always leads to the Map.
• — leads you to related Biolinks.
• Blue Light — leads you to Node called Blue Light.
• increases — opens Biolink «Blue Light increases VEGF».

Icons on the left and colors — is a way to visually code how two Nodes interact within the Biolink.

OK, nice!